S01. How far are we with AI based drug discovery?
S02. Bio company valuation, bubble or not?
S03. Bio cold chain logistics
S04. Target Product Degradation(TPD) and Target Product Upregulation
S05. Impact of biotech industry & ESG
S06. Biomimetic technology, beyond the borders of animal study and clinical trial
S07. CDMO Strategy
S08. The path to commercialization - Partnering to unblock value in your company
S09. Bio convergence: Korea, IT to BT powerhouse
S10. Exosome and its infinite application
S11. Defend your trade secrets
S12. How digital healthcare is redefining the future of insurance in Korea
S13. Clinical status of alzheimer treatments
S14. The future of genome editing technology
S15. Domestic/overseas listing strategy
S16. Post pandemic global clinical trial - Trends in drug development: innovation, analysis and execution. Changes and adoption with COVID-19
S17. Korean conglomerate dive into biohealth industry
S18. Preventative medicine through In-silico Trial
S19. IP Strategy in Bio Healthcare
O&M HALYARD
UPS HEALTHCARE (MARKEN)
ENVIROTAINER
CYTIVA
S.LAB
MERCK
SATORIUS KOREA
KIRAMS
LBTA
ORACLE
THERMO FISHER SCIENTIFIC
EMBASSY OF BELGIUM
XCELLTHERAPEUTICS CO., LTD.
LONZA
AWS
SIDLEY AUSTIN LLP
CLARIVATE
AMICOGEN
BIO MARKETING LAB(BML)